In this episode of the Psychedelic Spotlight podcast, we spend some time with Timothy Ko who is the CEO of Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) (FSE: “1XU1”), a biotechnology company focused on developing psychedelic medicines to treat addiction.

In our conversation with Mr. Ko, we discuss how the company plans to utilize the psychedelic compound DMT to address the global addiction crisis and use genetics to develop more effective personalized treatment regimens for patients.

*To learn more about the company featured in this episode and the work they’re doing, visit their website: https://entheonbiomedical.com

*Get the latest industry news around all things psychedelics by visiting our website, and be sure to subscribe to our newsletter to never miss a thing.

Subscribe to our YouTube channel: https://bit.ly/3prTiCI
Visit our Website: https://psychedelicspotlight.com
Follow us on Instagram: https://instagram.com/psycspotlight
Like us on Facebook: https://facebook.com/PsychedelicSpotlight
Follow us on Twitter: https://twitter.com/PsycSpotlight

*This episode was recorded on May 5, 2021.

#Psychedelics #Stocks #News #Business #DMT # Clinincal #Addiction #Genetics

source

Similar Posts

Mendeleyev: Music, Magic, Mushrooms

Mendeleyev: Music, Magic, Mushrooms

Listen

In the realm where music meets the mystical, few artists embody the fusion of psychedelic exploration and sonic innovation like Mendeleyev.

How Risky is MindMed Stock? (MMED / MMEDF Risk Assessment)

How Risky is MindMed Stock? (MMED / MMEDF Risk Assessment)

Listen, Videos

Today, we have a different episode for you..Usually we talk about all the things I am excited for when it comes to MindMed and MindMed stock, but today, we will visit the darker side by discussing how risky is the MindMed stock.
It is important for all psychedelic investors to grasp that MindMed is not a sure deal. Yes, I believe that long term it will succeed, but there are certain things that could go wrong.

We will cover the very real risks involved in investing in MindMed such as:
1. The possibility of MindMed’s medicines being inefficacious
– Whether of not MMED’s clinical trials succeed
2.MindMed’s incertain long term profitability
– Can the company scale production and training protocols?
3.MindMed Stock volatility
– MindMed’s market cap
– Future short interests

MindMed trades on the Canadian NEO Market as (MMED) and American OTC market as (MMEDF)

MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://mindmed.co/wp-content/uploads/2020/11/end-of-year-2019-discussion.pdf

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own